P4 · Lab
Mirxes
What Mirxes says about itself
Mirxes is a Singapore-founded biotech diagnostics company specializing in miRNA-based liquid biopsy and early cancer detection, achieving Southeast Asia's first biotech unicorn status upon its HKEX IPO in May 2025. Its flagship products include GASTROClear (the world's first blood test for gastric cancer early detection, FDA Breakthrough Device designated) and LUNGClear for lung cancer. The company operates clinical sequencing, precision multiomics, and biobanking services through a public-private partnership center for specialty molecular testing in Singapore.
Source: mirxes.com, the organization's own site.
What the Atlas verified
Mirxes is one of 309 organizations recorded in the Atlas of the Healthspan Economy, one of 25 in Singapore and one of 106 in Asia.
Relationships
Key people
- Zhou Lihan (Co-Founder and CEO, PhD Biochemistry NUS); Zou Ruiyang (Co-Founder and CTO, PhD NUS-MIT Alliance); Prof. Too Heng Phon (Co-Founder and Chief Scientific Advisor, NUS)